BCEHS began enrolling patients in the Pre-hospital Tranexamic Acid for Traumatic Brain Injury Study (TXA study) on November 23, 2015.
Although TXA is approved for hemorrhagic shock, this study examines whether TXA initiated in the pre-hospital setting will improve neurologic outcome for moderate to severe (pre-hospital GCS < 12) traumatic brain injury.
The study, a phase II clinical trial, is seeking to determine if either of two different doses of TXA (1 gram pre-hospital followed by 1 gram in the hospital or 2 grams pre-hospital) is superior to placebo. All health care providers are blind to the drug being administered.
Richmond critical care paramedics screen, enroll and administer the study medication. This study is unique in that an on-call research assistant must meet the transferring crew within 10 minutes of the patient's arrival to the emergency department.
BCEHS Dispatch Operations is essential to this study. BCEHS dispatchers screen incoming traumatic injury calls and alert the critical care paramedic crew of potential for enrollment in the TXA study. As soon as enrollment is confirmed by the paramedics, BCEHS Dispatch Operations staff notifies the research assistant who meets the paramedic crew in the emergency department. Patients must be transferred to either the Royal Columbian or Vancouver General hospitals.
This TXA study is the final study in the 10 year history of the Resuscitation Outcomes Consortium, in which BCEHS and the BC Resuscitation Outcomes Consortium have featured prominently.
Further information about the study can be found on the Clinical Trials website.